

Chronic renal failure worsens ischemic stroke severity and

neurological consequences in mice





François Brazier^{1,2,3}, Maryam Assem^{1,2,3}, Lucie Hénaut¹, Saïd Kamel^{1,2}, Ziad A. Massy^{4,5}, Jean-Marc Chillon^{1,2},


¹ Inserm U1088, CURS, Amiens, 80054 France - ² Faculty of Medicine and Pharmacy, University of Picardie Jules Verne, Amiens, 80000 France – ³ Division of Nephrology, Amiens University Hospital, 80054 France – ⁴ Ambroise Paré University Hospital, Nephrology, Boulogne-Billancourt, 92104 France - 5 Inserm U1018, CESP, UVSQ, Villejuif, 94807 FRANCE.



INTRODUCTION AND AIM

Stroke is the third most common cause of cardiovascular death in patients with chronic renal failure (CRF). To date, data on the impact of CRF on the cerebral circulatory system are scarce and identification of underlying causes and successful medical treatments remains a major challenge. The present study sought to evaluate the impact of CRF on the severity of ischemic stroke 6 weeks after CRF installation.

MATERIALS AND METHODS



RESULTS


Figure 1. CRF worsens stroke-induced brain ischemia and hippocampal, cortical and infracortical loss of neurons as compared to SHAM operated mice.


Bregma -2.12 mm

CRF

Contralateral


Ipsilateral








A. Evaluation of total brain infract volume in SHAM (n=10) and CRF (n=11) mice. Results are expressed as mean ± SEM. *: p<0.05 CRF versus SHAM operated mice (Student t test). B., C., and D. Contra- and ipsilateral evaluation of neuronal loss in the hippocampus (B.), cortex (C.) and infracortex (D.) of CRF and SHAM operated mice (Cresyl violet staining, Gx25). AH: Ammon's horn; DG: Dentate gyrus; IA. Ischemic Area.

Figure 2. CRF amplifies stroke-induced decrease in mice neuroscore (A), resistance to tiredness (B) and muscular strength (C,D) as compared to SHAM operated mice.









Neurological evaluations. All evaluations were performed on SHAM and CRF mice 1 day before (D-1) and 1 and 2 days (D1 / D2) after stroke induction. A. Neuroscores (2 ways ANOVA: CRF/SHAM: p < 0.0001, days: p = 0.5439, interaction: p = 0.7781). B. Duration for which mice remained on the device during the <u>rotarod test</u> (2) ways ANOVA: CRF/SHAM: p = 0.0009, days: p = 0.4850, interaction: p = 0.1461). C. <u>Prehensile scores</u> (2 ways ANOVA: CRF/SHAM: p = 0.0008, days: p = 0.4648, interaction: p = 0.3226). D. Forelimbs muscular strength (2) ways ANOVA: CRF/SHAM: p = 0.0103, days: p = 0.8870, interaction: p = 0.6217).). Results are expressed as mean ± SEM. *: p<0.05 D1 or D2 versus D-1 within each group; \$: p<0.05 CRF versus SHAM mice

CONCLUSIONS

The present model appears to be suitable to investigate CRF-associated neurological disorders in mice. We showed that CRF increases stroke-induced brain ischemia and amplifies cortical, infracortical and hippocampal loss of neurons as compared to SHAM operated mice. CRF worsens stroke-induced motor and behavioral impairments, by decreasing mice muscular strengh, motor coordination and physical resistance to tiredness as compared to SHAM operated mice. Supplemental experiments are currently ongoing in order to identify the molecular mechanisms by which CRF worsens stroke-induced alteration of brain tissue integrity. The potential roles of specific and non-specific uremic toxicity in the genesis of these neurological abnormalities will soon be investigated.

The authors are grateful to La Région Picardie for awarding valuable support, especially for funding L.H. with a post-doctoral fellowship.

Α.



